Argen-X (0QW0) - Cash Flow Conversion Efficiency

Latest as of December 2024: 0.008x

Based on the latest financial reports, Argen-X (0QW0) has a cash flow conversion efficiency ratio of 0.008x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€40.45 Million ≈ $47.30 Million USD) by net assets (€5.31 Billion ≈ $6.21 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Argen-X - Cash Flow Conversion Efficiency Trend (2011–2024)

This chart illustrates how Argen-X's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Argen-X balance sheet liabilities for a breakdown of total debt and financial obligations.

Argen-X Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Argen-X ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Hasbro Inc
NASDAQ:HAS
0.713x
Unisplendour Corp Ltd
SHE:000938
0.180x
Jeronimo Martins SGPS SA
LS:JMT
0.198x
CP ALL Public Company Limited
BK:CPALL-R
0.044x
Investment AB Latour (publ)
ST:LATO-B
0.021x
mBank SA
WAR:MBK
0.724x
Juniper Networks Inc
NYSE:JNPR
0.066x
ALTEOGEN Inc
KQ:196170
-0.013x

Annual Cash Flow Conversion Efficiency for Argen-X (2011–2024)

The table below shows the annual cash flow conversion efficiency of Argen-X from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Argen-X stock valuation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €5.31 Billion
≈ $6.21 Billion
€-79.88 Million
≈ $-93.38 Million
-0.015x +85.33%
2023-12-31 €4.10 Billion
≈ $4.79 Billion
€-420.33 Million
≈ $-491.41 Million
-0.103x +66.55%
2022-12-31 €2.81 Billion
≈ $3.29 Billion
€-862.81 Million
≈ $-1.01 Billion
-0.307x -28.06%
2021-12-31 €2.53 Billion
≈ $2.96 Billion
€-606.81 Million
≈ $-709.43 Million
-0.239x -0.60%
2020-12-31 €1.67 Billion
≈ $1.96 Billion
€-398.46 Million
≈ $-465.85 Million
-0.238x -285.30%
2019-12-31 €1.18 Billion
≈ $1.38 Billion
€151.63 Million
≈ $177.27 Million
0.128x +228.46%
2018-12-31 €615.87 Million
≈ $720.02 Million
€-61.59 Million
≈ $-72.00 Million
-0.100x +5.62%
2017-12-31 €413.81 Million
≈ $483.79 Million
€-43.84 Million
≈ $-51.26 Million
-0.106x -163.35%
2016-12-31 €66.65 Million
≈ $77.92 Million
€11.15 Million
≈ $13.03 Million
0.167x +144.86%
2015-12-31 €40.76 Million
≈ $47.65 Million
€-15.19 Million
≈ $-17.76 Million
-0.373x -256.64%
2014-12-31 €60.90 Million
≈ $71.20 Million
€-6.37 Million
≈ $-7.44 Million
-0.105x +65.66%
2013-12-31 €29.97 Million
≈ $35.04 Million
€-9.12 Million
≈ $-10.66 Million
-0.304x +54.29%
2012-12-31 €16.65 Million
≈ $19.47 Million
€-11.09 Million
≈ $-12.96 Million
-0.666x -366.21%
2011-12-31 €27.90 Million
≈ $32.62 Million
€-3.98 Million
≈ $-4.66 Million
-0.143x --

About Argen-X

LSE:0QW0 UK
Market Cap
$25.11 Billion
€21.48 Billion EUR
Market Cap Rank
#1768 Global
#6 in UK
Share Price
€661.80
Change (1 day)
+0.00%
52-Week Range
€459.05 - €803.70
All Time High
€803.70
About

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more